We are delighted to announce the appointment of Carol Mackay and Dr James Mackay as our new Clinical and Medical Directors, respectively.

The two appointments follow a period of rapid expansion for the company, which has grown its headcount from 6 to just under 70 over the past year.

With a background as a radiographer, Carol joins the business from a large international genetic testing company. In a former role she was a registered manager for oncology services at a private London hospital, whilst James joins with 25 years of experience working as a clinical advisor to several commercial genetic testing companies.

Carol’s governance role will see her lead on all aspects of governance, compliance, quality management and improvement across Everything Genetic’s portfolio of services, whilst Dr. Mackay will provide clinical leadership, strategy, and oversight for the provision of the business’ hereditary genetic cancer testing offering, Antegenes.

Their joint expertise will be called upon to educate and advise patients with cancer and people with a family history of cancer, as part of the company’s pre- and post-consultative support package to help individuals make informed decisions following a genetic test.

Carol said: “Everything Genetic has proven itself to be a pioneer in its field, and I’m delighted to be joining the company at such a pivotal time as we emerge from the pandemic.

“Life sciences has grown in prominence throughout the last two years and the sector has learnt a great deal during Covid-19. So, to be joining such an innovative team at this time is really exciting, and I look forward to using my experience in the field to bolster its offering.”

Carol is currently working towards ISO accreditation for quality management (ISO 9001) and information security (ISO 27001).

James added: “With testing for Covid becoming as ubiquitous as face mask-wearing, we hope the lessons learnt by the public over the pandemic can be applied to other issues within society.

“That appetite for testing could be applied to other complex diseases like cancers and heart conditions, providing people with actionable insight into their own health pathways. It feels like we’re on the precipice of a pivotal time in a sector which could play a key role overcoming some of society’s biggest healthcare issues.”

Founded in 2016, Everything Genetic’s background is in genetic testing, determining a person’s risk of developing hereditary cancers and heart disease.

The company expanded its offering in 2020 into end-to-end rapid antigen lateral flow testing and PCR testing for individuals, employers and healthcare providers, and has gone on to sell more than a million Covid and genetic test kits.

The accelerated growth over the past two years has created dozens of new jobs within the business and allowed the company to invest over £1 million in acquisitions.

James Price, CEO at Everything Genetic, said: “The success of the business is a testament to the hard work and commitment from all of its employees, and we’re excited to have Carol and James on board to help further our progression and build on the renewed confidence the business has following such a strong period.

“The work we do at Everything Genetic is impactful to so many lives, whether screening for covid, cancer or heart disease, and we are dedicated to continuing to provide the best in testing that can be available to all.”

Everything Genetic continues to seek new employees to join its ambitious team, visit our careers page to see our available roles.